

Special Issue

Recent Prospectives in CAR T-based Therapy for Solid and Hematological Malignancies

Message from the Guest Editors

CAR T-cell therapy has been demonstrated to be effective in CD19-positive blood cancers; thus, this offers great hope for a wide range of aggressive tumors. Despite the great promise of CAR T-cell-based therapy, several challenges still exist such as cancer cells heterogeneity, abnormal signaling pathways involved in tumor progression, antigen escape, the hostile inhibitory tumor microenvironment, and T cells' dysfunction/exhaustion. All of these issues must be addressed before a full clinical application can begin. More recently, another T-cell therapy has taken hold, and we hope in this Special issue can provide advances in T cells engineered with Fc γ -chimeric receptors (CRs) redirected against solid tumors and blood malignancies. We also intend to highlight the most recent clinical trials with a focus on the rationale for using different types of CAR T cells, emphasizing the various ways in which such trials are designed to overcome specific hurdles, as well as how outcomes are reflected in improving therapeutic arsenals against various cancer types.

- CAR
- Fc γ -CR
- T cells
- solid tumors
- blood malignancies

Guest Editors

Dr. Carlo Cenciarelli

Institute of Translational Pharmacology, National Research Council of Italy, Rome, Italy

Prof. Dr. Hany E. Marei

Faculty of Veterinary Medicine, Department of Cytology and Histology, Mansoura University, Mansoura, Egypt

Deadline for manuscript submissions

closed (15 October 2022)



Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



mdpi.com/si/103824

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)





Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)



About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPUS / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).